Intensity Therapeutics, Inc. (INTS)
Nasdaq: INTS · Biological Products, (No Diagnostic Substances) · Shelton, CT · filing with the SEC since 2013
Who runs Intensity Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Bender Lewis H
President and CEO. First filing Jun 2023, latest Jul 20, 2026, 0 filings in all.
Officers reporting now
3
of 7 people with a filing in the last fifteen months
Directors reporting now
4
8 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bender Lewis H | President and CEO | Jun 2023 | Jul 20, 2026 | none |
| Talamo Joseph | Chief Financial Officer | Dec 2023 | Jul 20, 2026 | none |
| Wesolowski John M | Principal Accounting Officer | Jun 2023 | Jul 20, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Donovan Daniel | director | Jun 2023 | Jul 20, 2026 | none |
| Dubin Thomas I H | director | May 2024 | Jul 20, 2026 | none |
| Goldberg Mark A | director | Jun 2023 | Jul 20, 2026 | none |
| Leahy Emer | director | Jun 2023 | Jul 20, 2026 | none |
Earlier names on the record1, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.